Navigation Links
Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
Date:8/19/2008

une response to DNA vaccines. Vaxfectin(R)-formulated DNA vaccines have demonstrated good tolerability and significant immune responses in multiple animal models, including nonhuman primates, and recently underwent successful initial human testing with the company's H5N1 pandemic influenza DNA vaccines. Vaxfectin(R) has also demonstrated a dose-sparing effect with the commercial seasonal influenza and government-stockpiled H5N1 pandemic influenza vaccines. Vaxfectin(R) may have potential applications as an adjuvant for other protein-based vaccines as well. The company holds patents covering Vaxfectin(R) and its use with DNA vaccines and conventional vaccines against infectious diseases and cancer.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-loo
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
2. Nventa Develops Proprietary Vaccine Adjuvant
3. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
4. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
5. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
6. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks
9. Inhaled Steriods Used as Preventive Treatment Post 9/11
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 A pharmaceutical executive in ... with three issues he wanted the research and consulting ... external personnel (especially for secondary research) to maximize efficiency ... of increased workload , Automation of market research ... , How to implement and manage those automated ...
(Date:9/19/2014)... 19, 2014  Today DePuy Synthes Companies of ... plating systems featuring its proprietary variable angle locking ... trajectory to match patient anatomy and fracture pattern ... The systems are being introduced in conjunction with ... and the International Federation of Foot & Ankle ...
(Date:9/19/2014)... 2014 "Copay coupons," a drug ... brand drugs among patients with prescription drug coverage, may now ... new report  from the Department of Health ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... by the federal government. The ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. ... stress and family conflicts before surgery may face a ... study suggests. Investigators found that patients with a ... times greater risk for complications compared to those with ... long known that patient quality of life is a ...
(Date:9/19/2014)... "I have difficulty putting in my eye contacts, ... skin around my eyes during the struggle," said an ... a more convenient method of performing this task." , ... easier, more sanitary method of putting in contact lenses. ... saves time and effort, and helps prevent wrinkles around ...
(Date:9/19/2014)... of Mayo Clinic have discovered a defect in a ... of toxic protein in the brains of Alzheimer,s ... between neurons both significant contributors to this type ... of Neuron , offers the potential ... or rescue this pathway," says the study,s lead investigator, ...
(Date:9/19/2014)... 19, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, IX Web Hosting and Bluehost are ... “As is known to most people, VPS (Virtual ... physical server computer into many servers, each of ... on someone’s own dedicated computer,” the manager of ...
(Date:9/19/2014)... 19, 2014 BCC Research reveals in ... GLOBAL MARKETS , the global market for human antifungal ... by 2018, with a five-year compound annual growth rate ... growing at a steady 3.8% CAGR. , Given the ... sales, coupled with the incidence of increasing mortality and ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3
... Association of America Launches ,Treat It, Don,t Repeat ... a National Educational Campaign -, WASHINGTON, March 13 ... (OCD) reported their condition has,a negative impact on important ... life, according to a new national survey commissioned by ...
... NEW BRUNSWICK, N.J., March 13 Johnson &,Johnson ... Company Health Care,Conference on Thursday, March 20th at ... Colleen Goggins, Worldwide Chairman,Consumer Group will represent the ... Time)., The webcast will be available to ...
... spring, PORT WASHINGTON, N.Y., March 13 Spring ... to unemployment, foreclosures and gas at,an all-time high, consumers ... becoming more and more apprehensive about spending money,especially when ... a tough time trying to justify paying the high ...
... secure access to corporate resources for ... ... Germany-based Universa, the,country,s oldest private health insurance organization, sought a ... authentication solution. In the end, Universa selected Entrust,Inc. (Nasdaq: ...
... SOUTH SAN FRANCISCO, Calif., March 13 Rigel,Pharmaceuticals, Inc. ... Gower,the company,s chairman and chief executive officer, is scheduled ... Brothers Global Healthcare,Conference in Miami, Florida on Tuesday, March ... also scheduled to participate in a panel discussion titled,"Biotech ...
... Execution of Partnership Strategy Provides Nearly $450 Million ... and Committed Cash * 2008 Projected Net Operating Loss Less ... than $450 Million * Conference Call Webcast Thursday, March 13, 08:30 a.m. EDT ... http://www.isispharm.com , CARLSBAD, Calif., March 13 ...
Cached Medicine News:Health News:Video: New Survey Reveals More Than Half of Adults With OCD Say the Disorder Has a Negative Impact on Relationships at Home, Work and in Their Personal Life 2Health News:Video: New Survey Reveals More Than Half of Adults With OCD Say the Disorder Has a Negative Impact on Relationships at Home, Work and in Their Personal Life 3Health News:Lose Weight This Spring With Portion Control Diet Tool 2Health News:Enabling the Mobile Workforce ... Entrust Deploys Strong Authentication for German Health Insurance Expert 2Health News:Enabling the Mobile Workforce ... Entrust Deploys Strong Authentication for German Health Insurance Expert 3Health News:Rigel Announces Participation in Upcoming Investor and Partnering Conferences 2Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 2Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 4Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 5Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 6Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 7Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 8Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 9Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 10Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 11Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 12Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 13Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 14Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 15Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 16Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 17Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 18Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 19Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 20Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 21Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 22Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 23Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 24Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 25Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 26
... Advanced Magnetics' oral gastrointestinal imaging agent used ... from other abdominal structures and physiology. MRI ... abdomen without contrast agents is difficult because ... distinguished from the loops of the bowel. ...
... only isosmolar contrast medium (IOCM) available in the ... blood, VISIPAQUE was designed for patient safety and ... formulated with sodium and calcium in a ratio ... approval for use in children over one year ...
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
Hand surgery basic instrument set...
Medicine Products: